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doi:10.101Endothelial Dysfunction after Hematopoietic Stem Cell
Transplantation: Role of the Conditioning Regimen
and the Type of Transplantation
Marta Palomo,1 Maribel Diaz-Ricart,1 Carla Carbo,2 Montserrat Rovira,3
Francesc Fernandez-Aviles,3 Carmen Martine,3 Gabriela Ghita,3 Gines Escolar,1
Enric Carreras3There is endothelial activation and damage in hematopoietic stem cell transplantation (HSCT). The impact of
the conditioning and type of HSCTon endothelial dysfunction in the early phases of HSCT has been evalu-
ated. Plasma samples were obtained before and at different times after autologous and allogeneic HSCTwith
and without early complications. Changes in soluble markers of endothelial damage (VWF, ADAMTS-13,
sVCAM-1, sICAM-1, and sTNFRI) were measured. There were changes in all markers evaluated that fol-
lowed different patterns in auto and allo settings. For VWF and sTNRI, progressive increases from day
Pre to day 14 and to day 21 were observed in the auto and the allo group, respectively. ADAMTS-13 activity
correlated inversely with VWF levels. Levels of sVCAM-1 decreased until day 7, and raised significantly to day
14 and to day 21 in the auto and the allo HSCT, respectively. No significant changes were detected for
sICAM-1. Our results confirm that there is endothelial damage at the early phases of HSCT, apparently in-
duced by the consecutive effects of the conditioning, the proinflammatory agents used during transplanta-
tion, the translocation of endotoxins across the damaged gastrointestinal tract, and the engraftment.
However, the comparative analysis between patients with and without complications suggests that none
of these markers has diagnostic or prognostic value.
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The endothelium has been recognized as a highly
active metabolic and endocrine organ, producing
a multitude of different molecules, including vasoactive
peptide hormones, growth factors, coagulation factors,
and adhesion molecules. It is an active biologic
interface between blood and tissues that regulates the1Hemotherapy-Hemostasis Department, Centre de Diag-
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6/j.bbmt.2010.02.008delicate balance between vasoconstriction and vasodila-
tation, coagulation and fibrinolysis, proliferation
and apoptosis, as well as between transient adhesion
and diapedesis of blood-borne leukocytes [1,2]. The
endothelium is capable of a number of responses
to local challenges. Some stimuli can produce
a physiologic endothelial activation to maintain the
properties of the endothelium and its environment,
including changes in the vasomotor tone, development
of a pro-coagulant activity, increase of the leukocyte ad-
hesiveness, and the loss of its barrier function, allowing
the passage of certain elements and solutes through
the endothelial lining [1,2]. However, other stimuli
can originate a true endothelial dysfunction, which
produces not only abnormal functional changes but
also structural changes (nuclear vacuolization, edema,
and cytoplasm fragmentation, denudation, and lost of
adhesion to the extracellular matrix). Depending on the
extension of the damage, the endothelial dysfunction
can be localized (in 1 or several organs) or systemic [1-3].
During hematopoietic stem cell transplantation
(HSCT), endothelial cells (ECs) can be activated and
damaged by the chemoradiotherapy included in the
conditioning regimen, the cytokines produced by the985
986 Biol Blood Marrow Transplant 16:985-993, 2010M. Palomo et al.injured tissues, bacterial endotoxins translocated
through the damaged gastrointestinal tract, some
drugs used during the procedure (as granulocyte-
colony stimulating factor [G-CSF] or calcineurin
inhibitors), the complex process of the engrafment,
and allogeneic reactions with the donor-derived im-
mune cells [4], among others. There is evidence sug-
gesting that some complications appearing early after
HSCT, as veno-occlusive disease of the liver [5,6],
capillary leak syndrome [7], thrombotic microangiop-
athy (TMA) [8,9], engraftment syndrome (ES) [10],
diffuse alveolar hemorrhage [11], idiopathic pneumo-
nia syndrome, and graft-versus-host disease (GVHD)
[12,13], can have their origin in a localized or
systemic endothelial damage.
EC activation and damage can be evaluated through
the analysis of several solublemarkers, including plasma
thrombomodulin, von Willebrand factor (VWF), and
soluble forms of adhesion molecules [14], the enumera-
tion of circulating ECs [15], and the evaluation of mor-
phologic and functional changes induced on cultured
ECs [16,17]. The present study was designed as
a extension of our initial in vitro studies on the
proinflammatory and prothrombotic effects of the sera
of patients receiving HSCT on human umbilical vein
ECs in culture [4]. The effect of the different types of
HSCT, and the conditioning regimens applied, on the
integrity of the endothelium was evaluated in vivo.
The potential diagnostic and/or prognostic utility of
the soluble markers evaluated as indicators of endothe-
lial related complications in HSCT was also explored.PATIENTS AND METHODS
Patients
We included 46 selected patients (mean age 48.56
14.1 years, ranging from 23-71 years; 20 female, 26
male), suffering from hematologic diseases, and receiv-
ing autologous (n5 22) or allogeneicHSCT (n5 24, 7
from related and 17 from unrelated donors) in our in-
stitution from January 2006 to January 2007.Diagnosis
included acute lymphoblastic leukemia (ALL), (n5 3),
acute myelogenous leukemia (AML) (n5 10), chronic
lymphocytic leukemia (CLL) (n5 2), chronic myelog-
enous leukemia (CML) (n 5 1), Hodgkin lymphoma
(HL) (n 5 6) and non-Hodgkin lymphoma (NHL)
(n510), myelodysplastic syndrome (MDS) (n 5 2),
andmultiplemyeloma (MM) (n5 12). The 4 following
conditioning regimens were applied: (1) BEAM:
BCNU 300 mg/m2 at day 27; etoposide 400 mg/m2
at days 26, 25, 24, and 23; cytosine arabinoside
200mg/m2 at days26,25,24, and23; andmelphalan
(Mel) 140mg/m2 at day22 (n5 11); (2)MLF:Mel 100
mg/m2 at days 23 and 22 (n 5 11); (3) Cy/TBI:
cyclophosphamide 60 mg/kg at days 27 and 26 and
total body irradiation 12 Gy in 4 fractions at days 24,23, 22, and 21 (n 5 14); and (4) Flu/MLF: reduced-
intensity conditioning (RIC) with fludarabine 30 mg/
m2 at days 27 to 23, followed by Mel 70 mg/m2 at
days 23 and 22 (n 5 10). Cyclosporine (CsA) from
day 27 plus short course of methotrexate or
mycophenolate mofetil were administered for
GVHD prophylaxis in patients receiving Cy/TBI or
Flu/MLF conditioning, respectively.
Twenty-seven patients had an HSCT without
complications defined by the absence of signs of organ
dysfunction (bilirubin\2.0 mg/dL, urea\1.5 mg/dL,
lactate dehydrogenase (LDH)\300 U/L, glutamate-
pyruvate transaminase \100 U/L), absence of
GVHD, veno-occlusive disease (VOD), TMA, or sep-
sis, no need for plasma exchange (plasmapheresis, dial-
ysis, hemofiltration), no administration of fresh frozen
plasma or steroids, no respiratory failure, and no need
of ventilation or vasopressors.
Nineteen patients developed transplant-related
complications (TRC): engrafment syndrome (ES) in
the autologous group (n 5 10), and GVHD (n 5 7)
and VOD (n 5 2), both in the allogeneic HSCT. ES
was diagnosed in 5 patients from each treatment group
in the autologous setting, with the presence of nonin-
fectious fever (.38C) plus at least 1 of the following
events: pulmonary infiltrates with no signs of infection,
cardiac failure or pulmonary embolism; hypoxemia;
skin rash involving.25% of body surface area; started
24 hours before or after the first appearance of neutro-
phils in peripheral blood. Acute GVHD (aGVHD) in
patients receiving allogeneic HSCT was graded by
classical criteria [18]. Hepatic VOD was diagnosed
and classified by the presence of painful hepatomegaly,
fluid retention, and weight gain and elevated serum
bilirubin concentration .2 mg/dL, according to the
Baltimore criteria [19].
In addition, plasma samples from 5 additional pa-
tients developing TMA (diagnosis based on clinical
features characterized by neurologic disturbance,
microangiopathic hemolytic anemia, renal insuffi-
ciency, and thrombocytopenia) were collected at the
time of the thrombotic complication (41 6 18 days).
Control samples fromhealthy donors (n5 44,mean
age 34 6 16.2 years, ranging from 21 to 54 years; 18
female, 26 male) were included in each determination.
Informed consent was obtained from all patients
and controls for blood utilization. The study was ap-
proved by the ethical committee of the Hospital Clınic
and was carried out according to the principles of the
Declaration of Helsinki.Sample Collection
Blood samples were obtained at different time
points of the study: Pre (before starting conditioning
regimen), day 0 (immediately before the infusion of
the hematopoietic stem cells), and days 7, 14, and 21
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Figure 1. Changes in plasmatic levels of vWF and ADAMTS-13 activity. Graphs represent changes in VWF (C) and ADAMTS-13 activity (B) levels in
plasma samples from recipients of autologous HSCTwith BEAM and MLF conditioning treatments, and of allogeneic HSCTwith Cy/TBI and Flu/MLF
treatments, as indicated. Levels were determined at the different time points of the study: before starting conditioning regimen (Pre), immediately before
the infusion of the hematopoietic stem cells (day 0), and days 7, 14, and 21 after the HSCT. Data are expressed as ratios with respect to the Pre value and
correspond to mean 6 SEM (*P\.05; n 5 6, 5, 5, and 8 for the BEAM, MLF, Cy/TBI, and Flu/MLF, respectively).
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a central line to avoid contamination with endothelial
cells. Plasma samples were obtained by centrifugation
of blood at 800  g for 15 min and immediately stored
at220C until the day of the analysis.Analysis of Soluble Markers of Endothelial
Dysfunction
The levels of plasma VWF, sVCAM-1, sICAM-1,
and sTNFRI weremeasured by the enzyme-linked im-
munoabsorvent assay (ELISA) (AmericanDiagnostica,
Grifols SA, Barcelona, Spain; Chemicon,GrupoTaper
SA, Madrid, Spain; and HycCult biotechnology b.v,
Uden, The Netherlands, Diagnostica Stago SA).
ADAMTS-13 activity was analyzed in citrated plasma
by using a fluorescence resonance energy transfer assay
using a truncated synthetic 73-amino acid VWF pep-
tide as a substrate (FRETS-VWF73 assay) [20,21]. In
addition, the presence of IgG anti-ADAMTS-13
(Technoclone GmbH, Viena) was also explored in
those patients that developedHSCT-associated TMA.
All measurements were performed in duplicate and
concentrations determined from the standard curve
according to the manufacturer’s instructions.Statistics
Results are expressed as mean 6 standard error of
the mean (SEM) and as ratios with respect to values at
day Pre. Statistical analysis was performed with raw
data using the Student’s t-test for paired samples
and analysis of variance (ANOVA). Results wereconsidered statistically significant when P\ .05. The
SPSS statistical package 17.0.0 (SPSS Inc, Chicago,
IL) was used for all analyses.RESULTS
Changes in Plasma Levels of VWF
Changes in plasma VWF values from patients
without TRC followed different kinetics depending
on the type of transplant (see ratios on Figure 1).
In the autologous setting under treatment with
either BEAM orMLF, we found a progressive increase
in values of plasma VWF along the follow-up of the
patients until day 14, followed by a decrease from day
14 to day 21. In absolute numbers, levels of VWF in pa-
tients treated with BEAM were of 97.7% 6 15.7% at
day Pre, and increased to 126.1% 6 16.2% at day 0,
159.4% 6 25.8% at day 7, with a peak of 181.1% 6
22.9% at day 14 (P\ .05 versus day Pre), and decreased
to 164.0%6 26.3% at day 21. In patients treated with
MLF, VWF levels were of 81.0% 6 11.1% at day
Pre, increased to 95.1% 6 11.5% at day 0, 136.9% 6
11.1% at day 7, with a peak of 148.8% 6 12.1% at
day 14 (P \ .05 versus day Pre), and decreased to
137.0%6 12.7% at day 21.
In the allogeneic group, the increase in VWF
plasma levels after both treatments, Cy/TBI and Flu/
MLF,was statistically significant at all time points stud-
ied and persistent until day 21, beingmore notable with
Cy/TBI (see Figure 1). Values of plasma VWF in pa-
tients treated with Cy/TBI were of 108.7% 6 10.7%
988 Biol Blood Marrow Transplant 16:985-993, 2010M. Palomo et al.at day Pre, and increased to 142.6% 6 9.7% at day 0,
165.4% 6 12.2% at day 7, 174.6% 6 7.5% at day 14,
and 189.8% 6 15.2% at day 21 (P\ .05 versus day
Pre for all values). In patients treated with Flu/MLF,
VWFlevelswereof 95.2%6 7.0%atdayPre, increased
to 133.0% 6 8.4% at day 0, 150.2% 6 9.7% at day 7,
157.8% 6 12.9% at day 14, and 169.2% 6 12.4% at
day 21 (P\ .05 versus day Pre for all values).
No significant differences were observed when
comparing the initial levels of VWF in the 4 groups
of patients (day Pre) with levels in a group of controls
(83.5% 6 11.3%, mean 6 SEM, n 5 44).Modifications in the ADAMTS-13 Activity
The activity of the metalloprotease ADAMTS-13
in plasma from patients without TRC showed a nega-
tive association with plasmaVWF levels (see Figure 1).
Although basal ADAMTS-13 activity values (day Pre)
were in the normal range, there was certain variability
between the 4 groups under study (82.1% 6 6.1% in
BEAM, 125.2% 6 7.7% in MLF, 88.5% 6 7.5% in
Cy/TBI, and 108.8%6 7.1% in Flu/MLF). A decline
in the protease activity after the conditioning regimen
appeared to be a constant finding.
In absolute values, ADAMTS-13 activity in the pa-
tients treated with BEAMwas of 82.1%6 6.1% at day
Pre, 80.7% 6 5.4% at day 0, 69.7% 6 6.5% at day 7,
59.4% 6 6.1% at day 14 (P\ .05 versus day Pre), and
66.8% 6 8 .8% at day 21. In patients treated with
MLF, ADAMST-13 activity was of 125.2% 6 2.7%
at day Pre, 101.8% 6 7.1% at day 0, 114.3% 6Cy/TBI
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Figure 2. Changes in the levels of sVCAM-1 and sICAM-1 in patientswithoutT
in soluble VCAM-1 and ICAM-1 levels in plasma from recipients of autologous
logeneicHSCTwithCy/TBI (:) and Flu/MLF (D) treatments. Levelswere determ
regimen (Pre), immediately before the infusion of the hematopoietic stem cells (
with respect to the Pre value and correspond to mean6 SEM (*P\0.05; n59.1% at day 7, 95.4% 6 6.7% at day 14 (P\ .05 vs.
day Pre), and 92.9% 6 9.9% at day 21. In the alloge-
neic setting, ADAMTS-13 activity in patients under
Cy/TBI treatment was of 88.5% 6 7.5% at day Pre,
88.1% 6 8.4% at day 0, 78.4% 6 4.5% at day 7,
61.7% 6 9.1% at day 14 (P \ .05 versus day Pre),
and 81.5% 6 14.3% at day 21. In patients treated
with Flu/MLF, ADAMTS-13 activity was of 108.8%
6 7.2% at day Pre, 92.0% 6 7.0% at day 0, 82.7%
6 9.1% at day 7, 69.3%6 9.9% at day 14 (P\ .05 ver-
sus day Pre), and 72.1% 6 7.6% at day 21.
Moreover, during the present study, we had the
opportunity to evaluate 5 cases of TMA. Evaluation
of ADAMTS-13 activity and VWF levels was carried
out at the time of diagnoses. In these patients,
ADAMTS-13 activity was reduced (42.3% 6 5.9%,
mean 6 SEM for the n 5 5), and no inhibitor against
ADAMTS-13 was detected in any of the samples. The
plasma levels of VWF in the 5 patients were signifi-
cantly higher than control values (180%6 20% versus
83.5% 6 11.3%, P\ .05).Presence of Soluble Adhesion Molecules
VCAM-1 and ICAM-1 in Plasma
Changes in the presence of the soluble endothelial
dysfunction markers VCAM-1 and ICAM-1 in plasma
samples from patients without TRC from the autolo-
gous and allogeneic groups are shown in Figure 2, ex-
pressed as ratios. As a general observation, the
kinetics for sVCAM-1 changes along the study were
similar when comparing BEAM and MLF, in theMLF
FLU/MLF
sICAM-1
0
0,5
1
1,5
2
2,5
sICAM-1
0,5
1,5
0
1
2
2,5
Pr ay 0 Day 7 Day 14 Day 21
Pr
e D
e Day 0 Day 7 Day 14 Day 21
RC from the autologous and allogeneic groups.Graphs represent changes
HSCTwith BEAM (C) and MLF (B) conditioning treatments, and of al-
ined at the different time points of the study: before starting conditioning
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Figure 3. Levels of plasmatic soluble TNF receptor I in patients with-
out TRC. Graphs representing changes in soluble TNFRI levels in plasma
from recipients of autologous HSCTwith BEAM (C) and MLF (B) con-
ditioning treatments, and of allogeneic HSCTwith Cy/TBI (:) and Flu/
MLF (6) treatments. Levels were determined at the different time
points of the study: before starting conditioning regimen (Pre), immedi-
ately before the infusion of the hematopoietic stem cells (day 0), and
days 7, 14, and 21 after the HSCT. Data are expressed as ratios with re-
spect to the Pre value and correspond to mean6 SEM (*P\.05; n5 6,
5, 5, and 8 for the BEAM, MLF, Cy/TBI and Flu/MLF, respectively).
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and Flu/MLF, in the allogeneic group. No significant
changes were detected when analyzing plasma levels
of sICAM-1.
In the autologous group, we observed a slight de-
cline in sVCAM-1 from day Pre to day 0 (from 283.9
6 32 ng/mL at day Pre to 237.7 6 12.4 ng/mL at
day 0 in patients treated with BEAM, and from 484.1
6 35.1 ng/mL at day Pre to 393.8 6 34 ng/mL in
the MLF group), remaining similar until day 7
(259.8 6 69.5 ng/mL in BEAM, 349.3 6 49.2 ng/
mL in MLF), increasing significantly to a maximum
peak at day 14 (439.8 6 70.3 ng/mL in BEAM, 583.3
6 65.8 ng/mL in MLF, P\ .05 for both with respect
to each Pre value), and decreasing slightly from day 14
to day 21 (409.6 6 95.4 ng/mL in BEAM, 514.1.3 6
49.6 ng/mL in MLF).
Changes of sICAM-1 levels in the same group of
patients were not as notable as those observed for
sVCAM-1, and showed a moderate tendency to
increase until day 14 (see Figure 2). In absolute num-
bers for the BEAM group, levels of sICAM-1 were of
189.5 6 24.7, 196.6 6 23.6, 208.1 6 7.8, 284.7 6
58.2, and 241.1 6 24.2 ng/mL, at days Pre, 0, 7, 14,
and 21, respectively. For the MLF group, levels were
of 194.7 6 25.1, 183.3 6 24.5, 197.6 6 48.6, 261.2
6 65.4, and 245.8 6 18.3 ng/mL, at days Pre, 0, 7,
14, and 21, respectively.
In the allogeneic group and in association with
both treatments, Cy/TBI and Flu/MLF, the plasma
sVCAM-1 levels decreased significantly after the con-
ditioning regimen (from 588.9 6 149.8 ng/mL at day
Pre to 289.8 6 89.9 ng/mL at day 0, P \ .05, for
Cy/TBI, and from 711.5 6 170.6 ng/mL at day Pre
to 642.6 6 129.9 ng/mL at day 0, P\ .05), followed
diverging tendencies from day 0 to day 7 (314.4 6
60.3 ng/mL in Cy/TBI and 405.6 6 84.9 ng/mL in
Flu/MLF), and increased progressively to day 14
(572.5 6 121.3 and 685.6 6 138.1 ng/mL in Cy/TBI
and FLU/MLF, respectively) and significantly to day
21 (750.1 6 125.9 and 1001.1 6 172.2 ng/mL in Cy/
TBI and Flu/MLF, respectively, P \ .05 for both
with respect to Pre value).
Changes in sICAM-1 levels showed the same ten-
dency as that observed for sVCAM-1, although much
lower and never reached statistical significance.
No significant differences were observed when
comparing the initial levels of both sVCAM-1 and
sICAM-1 in the 4 groups of patients (day Pre) with
levels in a group of controls (434.7 6 31.5 ng/mL
and 247.2 6 21.5 ng/mL, respectively, mean 6
SEM, n 5 44).Soluble TNF Receptor I Plasma Levels
Profiles of plasmatic soluble TNF receptor I in
patients without TRC are represented in Figure 3.In the autologous group, the analysis of TNFRI
showed a progressive increase from day Pre (1160.7
6 358.6 pg/mL in BEAM and 889 6 76.8 pg/mL in
MLF group) to day 14, at which values reached a statis-
tical significant peak (2299.3 6 805 pg/mL in BEAM
and 1420.6 6 135 pg/mL in MLF) (P\ .05 respect
day Pre) and decreased to day 21 (1642.6 6 140.5
pg/mL in BEAM and 1273.36 169.9 pg/ml in MLF).
In the allogeneic setting, we observed a progressive
increase of soluble TNFR I from day Pre (858.8 6
126.4 pg/mL in Cy/TBI and 910.4 6 140.4 pg/mL
in Flu/MLF) to day 21, being much more notable in
Flu/MLF than in Cy/TBI group (2562.3 6 617.1
pg/mL, and 1606 6 411.8 pg/mL, respectively).
No significant differences were observed when
comparing the initial levels of both TNFRI in the 4
groups of patients (day Pre) with levels in a group of
controls (1007.9 6 211.5, n 5 44).
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Figure 4. Kinetics of VWF in patients with TRC versus those without
complications. Graphs show VWF levels in recipients of autologous
HSCT (a) and allogeneic HSCT (b and c) with () and without (o) trans-
plant related complications. ES 5 engraftment syndrome (n 511);
GVHD 5 graft-versus-host disease (n 5 7); VOD 5 venooclusive dis-
ease (n 5 2). Data are expressed as absolute values in % (mean 6
SEM) (*P\.05; for days 7, 14, and 21 versus day Pre).
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Markers Analyzed
When comparing the kinetics for VWF in patients
with TRC versus those without complications, some
differences could be observed (see Figure 4). In the
auto group, those patients that developed ES showed
consistently higher levels of VWF than those that
did not develop any complication associated with
HSCT. When analyzing allogeneic HSCT recipients
who developed GVHD or VOD, we also found higherVWF levels than in patients without any complication,
although no statistical significance was reached. In
fact, changes in plasma levels of VWF along the
HSCT treatment versus day Pre reached statistical sig-
nificance at the same time points (days 7, 14, and 21,
P\ .05 in all cases) in both groups of patients, with
TRC and without complications (Figure 4).
Comparison of values for ADAMTS-13 activity,
sVCAM-1, sICAM-1, and sTNFRI among patients
with and without complications in each group did
not show a clear tendency and never reached statistical
significance (data not shown).DISCUSSION
We have previously demonstrated, by using an in
vitro approach, that the exposure of ECs in culture
to sera from patients that have received an HSCT
causes endothelial activation and damage, and that
these effects are not limited to the allogeneic but also
to the autologous setting [4]. In the present study, we
have extended our investigation to characterize the
proinflammatory effect of the different conditioning
regimens commonly applied in both modalities of
HSCT, and to find potential diagnostic and/or prog-
nostic markers of the early TRC apparently originated
by endothelial damage. We have observed changes
in plasma levels of VWF, ADAMTS-13 activity,
sVCAM-1, and sTNFRI in association with both types
of transplant, although following different kinetics.
The degree of these changes was related to the inten-
sity of the conditioning treatment. Although all these
markers are good indicators of endothelial activation
and damage, from the comparative analysis of the
results from patients with and without complications,
it can be derived that none of these markers seems to
have prognostic value.
The evaluation of changes in the release of VWF
revealed different endothelial activation kinetics dur-
ing HSCT probably depending on the conditioning
regimen, the use of G-CSF or CsA, the translocation
of endotoxins during the period of aplasia, the engraft-
ment and, probably, the allo-reactivity. The release of
VWF at the moment of the allogeneic transplant (day
0) is persistently higher than in the autologous setting,
a result that is in accordance with the obtained by Salat
et al. [14]. This fact could be explained by the higher
cytotoxic effect of Cy in combination with TBI [22],
or by the well-known endothelial toxicity of Flu [23]
and MLF. It is interesting to point out that in all our
studies the toxic effect of MLF on the endothelium is
similar to that exerted by BEAM, which is a regimen
traditionally considered more intense than MLF. In
addition, in the allo setting a role of the CsA adminis-
tered from day 27 could not be excluded. It has been
clearly demonstrated that CsA produces endothelial
Biol Blood Marrow Transplant 16:985-993, 2010 991Soluble Markers of Endothelial Damage in HSCTdamage and induces the release of VWF [24,25]. More
difficult to explain is the evolution of VWF levels from
day 0 to day 114 in autologous HSCT and to 121 in
allogeneic HSCT. In the auto setting, the use of G-
CSF, agent with a well-known proinflammatory effect
[26], can contribute to the endothelial damage from
day 17 to day 114. Similarly, in the allo setting CsA
can contribute to the damage observed along all the
study period. However, these 2 factors could not ex-
plain the progressive increase in VWF levels from
day 0 to 17 in autologous HSCT and up to day 121
in allogeneic HSCT. We believe that this observation
can be the consequence of both the translocation of en-
dotoxins through the damaged gastrointestinal tract
during the aplastic phase, followed by the endothelial
dysfunction that the complex process of engraftment
may induce. From day 0, the stem cell infused adhere
to bonemarrow endothelium interacting with selectins
and several surface adhesion molecules as VCAM [27].
After adherence, the transendothelial migration and
intraparenchymal homing to hematopoietic niches
take place [28]. Finally, after homing and proliferation,
the opposite process take place, which results in the re-
lease of neutrophils to peripheral blood, a process that
usually occurs between days 9 and 12 in autologous
HSCT and between days 14 and 20 in allogeneic
HSCT. Finally, a possible role of allo-reactivity in
this late period of allo-HSCT could not be excluded.
Althought other studies had evaluated several soluble
markers after day 128 [14,29,30], unfortunately, the
design of our study did not allow the evaluation of
the endothelial function after day 121.
ADAMTS-13 activity results were in good inverse
correlation with those obtained for VWF, as previ-
ously reported by Mannucci et al. [31]. It is interesting
to note that ADAMTS-13 activity decreased signifi-
cantly when VWF values increased around 50% over
the initial value. In addition, ADAMTS-13 activity in
the patients included in the study never decreased
under 60%, with the exception of those patients devel-
oping TMA in which ADAMTS-13 activity was of
42.3% 6 5.9% (value in the normal range). These
observations contribute to discard a pivotal role of
the metalloproteinase in the development of TMA
associated with the HSCT [29].
The release of soluble forms of adhesion receptors
sVCAM-1 and sICAM-1 is a reflection of the activa-
tion of the endothelium [32]. Our results showed a sig-
nificant decrease of sVCAM-1 along the conditioning
treatment. This decrease was more notable after the
conditioning with Cy/TBI, probably because of the
high intensity of this treatment. After this initial de-
cline, these receptors increased following the same ki-
netics observed for VWF depending on the type of
HSCT. Conditioning implies the use of aggressive im-
munosuppressive and cytotoxic treatments that may
interfere with the synthesis of proteins. The inducedexpression of VCAM-1 and ICAM-1 is largely depen-
dent on synthesis of new mRNA and protein because
there are no storage forms of this endothelial adhesion
proteins [33]. In the auto setting, levels of sVCAM
raised from day 17, at which G-CSF is administered,
to day114, just after the engraftment time. In the allo
setting, the progressive increase in sVCAM-1 levels
could be mainly because of the engraftment and CsA
toxicity. The fact that values of sVCAM-1 were more
relevant than those of sICAM-1 could be attributed
to a more restricted expression of the former to the
endothelium [34], and it suggests a direct endothelial
effect of the conditioning process. Apart from this,
because the kinetics of these adhesive molecules
correlate with the presence of inflammatory cells in
the circulation, the role of leukocytes along the
HSCT treatment cannot be disregarded. Leukocytes
could contribute with the release of either proinflam-
matory cytokines or even adhesion molecules to the
circulation.
sVCAM-1 has been shown to increase in response
to proinflammatory cytokines such as tumor necrosis
factor-alpha (TNF-a), which we have evaluated
through the release of sTNFRI. Similar to the other
markers evaluated in this study, the kinetics of
sTNFRI changes between the 2 types of HSCT. We
were unable to detect reliable changes in TNF-a in
the plasma of the patients studied (data not shown),
as reported by Andersen et al. [35]. In fact, a variable
tendency in the changes of plasma levels of TNF-
a has been described by other authors in many other
pathophysiologic conditions [36]. Presence of soluble
receptors for TNF-a (sTNFR) has been reported to
follow a good correlation with the cytokine. Soluble
TNFRs act as inhibitors of TNF-a activity and repre-
sent a natural protective mechanism against the cyto-
toxic effect of this protein by preventing its binding
to the surface receptors. In fact, TNF-a circulates
bound to sTNFRI in a cryptic inactive form [37].
The expression of sTNFRI seems to be regulated
not only by presence of TNF-a but also by other
proinflammatory mechanisms. In the present study,
sTNFRI increased from Pre to 0 in the allogeneic set-
ting, but also in the autologous. In addition, levels of
plasma sTNFRI in the patients studied followed kinet-
ics similar to those described for VWF suggesting the
same pathogenetic events previously mentioned. The
main difference was that in the allogeneic setting these
levels were higher in association with the Flu/MLF
treatment, although this observation is of unclear
clinical significance.
The comparative analysis of data between patients
with and without complications did not show a clear
tendency or statistical significance for all the markers
analyzed, but did for VWF levels. Levels of plasma
VWF in patients with complications were consistently
higher in all groups studied, although these differences
992 Biol Blood Marrow Transplant 16:985-993, 2010M. Palomo et al.never reached statistical significance. Therefore, from
the present study we can conclude that the markers
evaluated have to be ruled out as prognostic markers
of endothelial related complications associated to the
HSCT. These results may be ascribed either to the
nature of the markers or to the low number of patients
included, although they may suggest additional mech-
anisms for the development of these complications in
addition to the endothelial damage.
In conclusion, there is endothelial activation and
damage in association with both autologous and allo-
geneic HSCT, as demonstrated by the increased
plasma levels of the markers evaluated. The kinetics
of changes observed in patients without transplant-
related complications indicate that the engrafment
induces maximal endothelial activation in both autolo-
gous and allogeneic HSCT. The progressive increase
in the markers evaluated in the allogeneic setting
may be indicating that the initiation of the allogenicity
process is the main cause of endothelial damage in this
type of HSCT. Although previous reports strongly
suggest that endothelial damage may play a major
role in the development of TRC, our present results
suggest additional mechanisms. Search for diagnostic
and prognostic markers, and for prevention strategies
should be the subject of future investigation.ACKNOWLEDGMENTS
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